Question 50 (part 2) · LEK · Hepatocellular carcinoma (HCC)
Screening for hepatocellular carcinoma (HCC) involves:
- A. an ultrasound and alpha-fetoprotein measurement every 12 months in high-risk patients i.e. those with cirrhosis caused by hepatitis B and C, hemochromatosis, alcohol.
- B. an ultrasound and alpha-fetoprotein measurement every 6 months in high-risk patients i.e. those with cirrhosis caused by hepatitis B and C, hemochromatosis, alcohol.
- C. an ultrasound and alpha-fetoprotein measurement every 6 months in high-risk patients i.e. those with cirrhosis caused by hepatitis B and C, hemochromatosis, but not alcohol.
- D. an ultrasound and alpha-fetoprotein measurement every 12 months in high-risk patients i.e. those with cirrhosis caused by hepatitis B and C, hemochromatosis, but not alcohol.
- E. an ultrasound and alpha-fetoprotein measurement every 12 months in high-risk patients i.e. those with cirrhosis caused only by hepatitis B and C.
Hint
Recall the surveillance interval derived from HCC doubling time, and ask whether the cause of cirrhosis matters.
The answer, the explanation and a note on every option are available once you log in. The account is free: topic tests, a mock exam, mistake review and statistics.
More questions on Oncology
- Which is true about gastrointestinal stromal tumours (GIST)?
- The gold standard in colorectal cancer prevention and screening is:
- Which of the following drugs is part of every treatment protocol of plasma cell myeloma in a patient prepared for an autologous stem cell transplant?
- Oncological patients at the highest risk of cardiological complications (including the development of dilated cardiomyopathy) are patients whose…
- Selected characteristics of gastric cancers according to Lauren classification are given below. Which of them describe intestinal type…
- Which of the following drugs used chronically reduces the risk of colorectal cancer (it is not recommended as prophylaxis of this type of cancer…